Intercellular Communication during Bone Remodeling

Osteoporosis, Two-Volume Set

Volumn , Issue , 2008, Pages 547-560

  Martin, T John ^a   Rodan, Gideon A ^b  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883939883     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012370544-0.50022-7     Document Type: Chapter

References (121)

1. Harris W.H., Heaney R.P. Skeletal renewal and metabolic bone disease. N Engl J Med 1969, 280:193-202.
2. Prestwood K.M., Pilbeam C.C., Burleson J.A., Woodiel F.N., Delmas P.D., Deftos L.J., Raisz L.G. The short term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 1994, 79:366-371.
3. Frost H.M. Dynamics of bone remodeling. Bone Biodynamics 1964, 315-333. Little, Brown, Boston.
4. Rodan G.A. Perspective: Mechanical loading, estrogen deficiency and the coupling of bone formation to bone resorption. J Bone Miner Res 1991, 6:527-530.
5. Parfitt A.M. Skeletal heterogeneity and the purpose of bone remodeling: Implications for the understanding of osteoporosis. Osteoporosis 1996, 315-319. Academic, San Diego, CA. R. Marcus, D. Feldman, J. Kelsey (Eds.).
6. Hauge M., Qvesel D., Eriksen E.F., Mosekilde L., Melsen F.E. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblast markers. J Bone Min Res 2001, 16:1575-1582.
7. Sakamoto S., Sakamoto M. Bone collagenase, osteoblasts and cell-mediated bone resorption. Bone and Mineral Research 1986, 49-102. Elsevier, Amsterdam. W.A. Peck (Ed.).
8. Chambers T.J., Darby J.A., Fuller K. Mammalian collagenase predisposes bone surfaces to osteoclastic resorption. Cell Tissue Res 1985, 241:671-675.
9. Chambers T.J., Fuller K. Bone cells predispose bone surfaces to resorption by exposure of mineral to osteoclastic contact. J Cell Sci 1985, 6:155-165.
10. Eriksen E.F. Normal and pathological remodeling of human trabecular bone: Three dimensional reconstruction of the remodeling sequence in normals and in metabolic disease. Endoci Rev 1986, 4:379-408.
11. Villanueva A.R., Kypikowski C., Parfitt A.M. A new method for identification of cement lines in undecalcified, plastic embedded sections of bone. Stain Technol 1986, 61:83-88.
12. Peerez-Amodio S., Beertsen W., Everts V. Pre-osteoclasts induce retraction of osteoblasts before their fusion to osteoclasts. J Bone Min Res 2004, 19:1722-1728.
13. Chen J., McKee M.D., Nanci A., Sodek J. Bone sialoprotein mRNA expression and ultrastructural localization in fetal porcine calvarial bone: Comparisons with osteopontin. Histochem J 1994, 26:67-78.
14. Hynes R. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1992, 69:11-25.
15. Eghbali-Fatourechi G.Z., Lamsam J., Fraser D., Nagel D., Riggs B.L., Khosla S. Circulating osteoblast-lineage cells in humans. N Engl J Med 2005, 352:1959-1966.
16. Winkler D.G., Sutherland M.K., Geoghegan J.C., Yu C., Hayes T., Skonier J.E., Shpektor D., Jonas M., Kovascevich B.R., Staehling-Hampton K., Appleby M., Brunkow M.E., Latham J.A. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003, 22:6267-6276.
17. van Bezooijen R.L., Roelen B.A., Visser A., van der Wee-Pals L., de Wilt E., Karperien M., Hamersma H., Papapoulos S.E., ten Dijke P., Lowik C.W. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004, 199:805-814.
18. Keller H., Nessel M. SOST is a target gene for PTH in bone. Bone 2005, 37:148-158.
19. Bellido T., Ali A.A., Gubrij I., Fu Q., O'Brien C.A., Manolagas S.C., Jilka R.L. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005, 146:4577-4583.
20. Skerry T.M., Bitensky L., Chayen J., Lanyon L.E. Early strain-related changes in enzyme activity in osteocytes following bone loading in vivo. J Bone Miner Res 1989, 4:783-788.
21. McSheehy P.M.J., Chambers T.J. Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology 1986, 118:824-828.
22. Thomson B.M., Saklatvala J., Chambers T.J. Osteoblasts mediate interleukin-1 stimulation of bone resorption by rat osteoclasts. J Exp Med 1986, 164:104-112.
23. Rodan G.A., Martin T.J. Role of osteoblasts in hormonal control of bone resorption: A hypothesis. Calcif Tissue Int 1981, 33:349-351.
24. Chambers T.J. The cellular basis for bone resorption. Clin Orthop Relat Res 1980, 151:283-293.
25. Takahashi N., Akatsu T., Udagawa N., Sasaki T., Yamaguchi A., Moseley J.M., Martin T.J., Suda T. Osteoblastic cells are involved in osteoclast formation. Endocrinology 1988, 123:2600-2602.
26. Suda T., Takahashi N., Martin T.J. Modulation of osteoclast differentiation. Endocr Rev 1992, 13:66-80.
27. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
28. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T., Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998, 139:1329-1337.
29. Kong Y.Y., Hoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., Morony S., Oliveira-dos Santos A.J., Van G., Itie A., Khoo W., Wakeham A. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
30. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gregg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W.J. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
31. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley I., Capparelli C., Scully S., Tan H.L., Xu W., Lacey D.L., Boyle W.I., Simonet W.S. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268.
32. Dougall W.C., Glaccum M., Charrier K., Rohirbach K., Brasel K., De Smedt T., Daro E., Smith J., Tometsko M.E., Maliszewski C.R., Armstrong A., Shen V., Bain S., Cosman D., Anderson D., Morrissey P.J., Peschon J.J., Schuh J. RANK is essential for osteoclast and lymph node development. Genes Dev 1999, 13:2412-2424.
33. Burgess T.L., Qian Y., Kautman S., Ring B.D., Van G., Capparelli C., Kelley Mm, Hsu H., Boyle W.I., Dunstan C.R., Hu S., Lacey D.L. The ligand for osteoprotegerin OPGLl directly activates mature osteoclasts. J Cell Biol 1999, 145:527-538.
34. Kwon B.S., Wang S., Udagawa N., Haridas V., Lee Z.H., Kim K.K., Oh K.O., Greene J., Li Y., Su J., Gentsz R., Aggarwal B.B., Ni J. TRI, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J 1998, 12:845-854.
35. Horwood N.J., Elliott J., Martin T.J., Gillespie M.T. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998, 139:4743-4746.
36. Thirunavukkarasu K., Halladay D.L., Miles R.R., Yang R.I.S., Galvin, Chandrasekhar S., Martin T.J., Onyia J.E. The osteoblast-specific transcription factor Cbfal regulates the expression of osteoprotegrin (OPG), a potent inhibitor of osteoclast differentiation and function. J Biol Chem 2000, 275:25163-25172.
37. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., Martin T.J. Modulation of osteoclast differentiation and function by the new members of the human necrosis factor receptor and ligand families. Endocr Rev 1999, 20:345-357.
38. Mohan S., Jennings J.C., Linkhart T.A., Baylink D.J. Primary structure of human skeletal growth factor: Homology with human insulin-like growth factor-11. Biochem Biophys Acta 1988, 966:44-55.
39. Mohan S., Baylink D.J. The role of IGF-11 in the coupling of bone formation to resorption. Modern Concepts of Insulin-like Growth Factors 1991, 169-184. Elsevier, New York.
40. Hauschka P.V., Mavrakos A.E., Iafrati M.D., Doleman S.E., Klagsbrun M. Growth factors in bone matrix: Isolation of multiple types by affinity chromatography on heparin sepharose. J Biol Chem 1986, 261:12665-12674.
41. Schmid C., Ernst M. Insulin-like growth factors. In Cytokines and Bone Metabolism 1992, 229-265. CRC Press, Boca Raton, FL.
42. Rodan S.B., Rodan G.A. Fibroblast growth factor and platelet-derived growth factor. Cytokines and Bone Metabolism 1992, 115-145. CRC Press, Boca Raton, FL.
43. Centrella M., McCarthy T.L., Canalis E. Transforming growth factor-beta and remodeling in bone. J Bone Joint Surg 1991, 73-A:1418-1428.
44. Ogawa Y., Schmidt D.K., Daschy J.R., Chang R.J., Glasser C.B. Purification and characterization of transforming growth factor beta2.3 and beta1.2 heterodimers from bovine bone. J Biol Chem 1992, 267:2325-2328.
45. Harris S.E., Sabatini M., Harris M.A., Feng J.Q., Wozney J., Mundy G.R. Expression of bone morphogenetic protein messenger. RNA in prolonged cultures of fetal rat calvarial cells. J Bone Miner Res 1994, 9:389-394.
46. Vukicevic S., Latin V., Chen P., Batorsky R., Reddi A.H., Sampath K. Localization of osteogenic protein-1 (bone morphogenetic protein-7) during human embryonic development: High affinity to basement membranes. Biochem Biophys Res Commun 1994, 198:693-700.
47. Vukicevic S., Paralkar V.M., Cunningham N.S., Gutkind J.S., Reddi A.H. Autoradiographic localization of osteogenin binding sites in cartilage and bone during rat embryonic development. Dev Biol 1990, 140:209-214.
48. Rydziel S., Ladd C., McCarthy T.L., Centrella M., Canalis E. Determination and expression of platelet-derived growth factor-AA in bone cell cultures. Endocrinology 1992, 130:1916-1922.
49. McCarthy T.L., Centrella M., Canalis E. Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor 1 in osteoblast-enriched cultures from fetal rat bone. Endocrinology 1989, 124:1247-1253.
50. McCarthy T.L., Centrella M., Raisz L.G., Canalis E. Prostaglandin E2 stimulates insulin-like growth factor 1 synthesis in osteoblast-enriched cultures from fetal rat bone. Endocrinology 1991, 128:2895-2900.
51. Turner R.T., Backup P.H., Sherman P.H., Hill E.L., Evans G.L., Spelsberg T.C. Mechanism of action of estrogen on intra membranous bone formation and regulation of osteoblast differentiation and activity. Endocrinology 1992, 131:883-889.
52. Shinar D.M., Endo N., Halperin D.I., Rodan G.A., Weinreb M. Differential expression of insulin-like growth factor-1 (IGF-1) and IGF-11 messenger ribonucleic acid in growing rat bone. Endocrinology 1993, 132:1158-1167.
53. Suva L.J., Seedor J.G., Endo N., Quartuccio H.A., Thompson D.D., Bab I., Rodan G.A. Pattern of gene expression following rat tibial marrow ablation. J Bone Miner Res 1993, 8:379-388.
54. Mohan S., Baylink D.J. Evidence that the inhibition of TE85 human bone cell proliferation by agents which stimulate camp production may in part be mediated by changes in the IGF-11 regulatory system. Growth Regul 1991, 1:110-118.
55. Centrella M., Horowitz M.C., Wozney J.M., McCarthy T.L. Transforming growth factor-beta gene family members and bone. Endoci Rev 1994, 15:27-39.
56. Komm B.S., Terpening C.M., Benz D.J., Graeme K.A., Gallegos A., Korc M., Greene G.L., Omalley B.W., Haussler M.R. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 1988, 241:81-84.
57. Noda M., Vogel R. Fibroblast growth factor enhances type 1 transforming growth factor gene expression in osteoblastlike cells. J Cell Biol 1989, 109:2529-2535.
58. Nakashima M., Nagasawa H., Yamada Y., Reddi A.H. Regulatory role of transforming growth factor-beta, bone morphogenetic protein-2, and protein-4 on gene expression of extracellular matrix proteins and differentiation of dental pulp cells. Dev Biol 1994, 162:18-28.
59. Heikinheimo K. Stage-specific expression of decapentaplegic-Vg-related genes 2, 4 and 6 (bone morphogenetic proteins 2, 4 and 6) during human tooth morphogenesis. J Dent Res 1994, 73:590-597.
60. Vukicevic S., Helder M.N., Luyten F.P. Developing human lung and kidney are major sites for synthesis of bone morphogenetic protein-3 (osteogenin). J Histochem Cytochem 1995, 42:869-875.
61. Globus R.K., Plouet J., Gospodarowicz D. Cultured bovine bone cells synthesize basic fibroblast growth factor and store it in their extracellular matrix. Endocrinology 1989, 124:1539-1547.
62. Somjen D., Binderman I., Berger E., Harell A. Bone remodeling induced by physical stress is prostaglandin E2 mediated. Biochem Biophys Acta 1980, 627:91-100.
63. Raisz L.G., Martin T.J. Prostaglandins in bone and mineral metabolism. Bone and Mineral Research 1984, 286-310. Elsevier, Amsterdam. W.A. Peck (Ed.).
64. Ducy P., Zhan R., Geoffroy V., Ridall A.L., Karsenty G. Osf2/Cbfal: A transcriptional activator of osteoblast differentiation. Cell 1997, 89:747-754.
65. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., Shimizu Y., Bronson R.T., Gao Y.H., Inada M., Sato M., Okamoto R., Kitamura Y., Yoshiki S., Kishimoto T. Targeted disruption of Cbfal results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764.
66. Ducy P., Starbuck M., Priemel M., Shen J., Pinero G., Geoffroy V., Amling M., Karsenty G. A Cbfal-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev 1994, 13:1025-1036.
67. Miao D., He B., Jiang Y., Kobayashi T., Soroceanu M.A., Zhao J., Su H., Tong X., Amizuka N., Gupta A., Genant H.K., Kronenberg H.M., Goltzman D., Karaplis A.C. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 11-34. J Clin Invest 2005, 115:2402-2411.
68. Martin T.J. Osteoblast-derived PTHrP is a physiological regulator of bone formation. J Clin Invest 2005, 115:2322-2324.
69. Spencer E.M., Liu C.C., Si E.C.C., Howard G.A. In vivo actions of insulin-like growth factor (IGF-1) on bone formation and resorption in rats. Bone 1991, 12:21-26.
70. Tobias J.H., Chow J.W.M., Chambers T.J. Opposite effects of insulin-like growth factor-1 on the formation of trabecular and cortical bone in adult female rats. Endocrinology 1992, 131:2387-2392.
71. Bagi C.M., Brommage R., Deleon L., Adams S., Rosen D., Sommer A. Benefit of systemically administered rh1GF1GFBP-3 on cancellous bone in ovariectomized rats. J Bone Miner Res 1994, 9:1301-1312.
72. Critchlow M.A., Bland Y.S., Ashhurst D.E. The effects of age on the response of rabbit periosteal osteoprogenitor cells to exogeneous transforming growth factor-beta. J Cell Sci 1994, 107:499-516.
73. Joyce M.E., Roberts A.B., Sportn M.B., Bolander M.E. Transforming growth factor and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biol 1990, 110:2195-2207.
74. Bonewald L.F., Wakefield L., Oreffo R.O.C., Escobedo A., Twardzik D.R., Mundy G.R. Latent forms of transforming growth factor beta (TGFbeta) derived from bone cultures: Identification of a naturally occurring 100-kDa complex with similarity to recombinant TGFbeta. Mol Endocrinol 1991, 5:741-745.
75. Oreffo R.O.C., Mundy G.R., Seyedin S.M., Bonewald L.F. Activation of the bone-derived latent TGF beta complex by isolated osteoclasts. Biochem Biophys Res Commun 1989, 158:817-823.
76. Martin T.J., Allan E.H., Fukumoto S. The plasminogen activator and inhibitor system in bone remodeling. Growth Regul 1993, 3:209-214.
77. Campbell P.G., Novak J.F., Yanosick T.B., McMaster J.H. Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology 1992, 130:1401-1412.
78. Gray C., Jones S.J., Boyde A. Topographically induced bone formation in vitro: Implications for bone implants and bone grafts. Bone 1996, 18:115-123.
79. Nakamura M., Udagawa N., Matuura S., Mogi M., et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 2003, 144:5441-5449.
80. Cleiren E., Benichou O., Van Hul E., Gram J., Bollerslev J., singer F.R., Beaverson K., Aledo A., Whyte M.P., Yoneyhama T., de Vernejoul M.C., Van Hul W. Albers-Schonberg disease (autosomal dominant osteopetrosis type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 2001, 10:2861-2867.
81. Lowe C., Yoneda T., Boyce B.F., Chen H., Mundy G.R., Soriano P. Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Nat Acad Sci USA 1993, 90:4485-4489.
82. Kasper D., Planells-Cases R., Fuhrmann J.C., Scheel O., Zeitz O., Ruether K., Schmitt A., Poet M., Steinfeld R., Schweizer M., Kornak U., Jentsch T.J. Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO J 2005, 24:1079-1091.
83. Aoki K., Didomenico E., Sims N.A., Mukhopadhyay K., Neff L., Houghton A., Amling M., Levy J.B., Horne W.C., Baron R. The tyrosine phosphatase SHP-1 is a negative regulator of osteoclastogenesis and osteoclast resorbing activity: Increased resorption and osteopenia in me(v)/me(v) mutant mice. Bone 1999, 25:261-267.
84. Grigoriadis A.E., Wang Z.Q., Cecchini M.G., Hofstetter W., Felix R., Fleisch H.A., Wagner E.F. C-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994, 266:443-448.
85. Sims N.A., Jenkins B.F., Quinn J.M., Nakamura A., et al. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest 2004, 113:379-389.
86. Martin T.J., Romas E., Gillespie M.T. Interleukins in the control of osteoclast differentiation. Crit Rev Euk Gene Expr 1998, 8:107-123.
87. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., Saito S., Inoue K., Kamateni N., Gillespie M.T., Martin T.J., Suda T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103:1345-1352.
88. Horwood N., Udagawa N., Elliott J., Grail D., Okamura H., Kurimoto M., Dunn A.I., Martin T.J., Gillespie M.T. IL18 inhibits osteoclast formation via T-cell production of GM-CSF. J Clin Invest 1999, 103:1345-1352.
89. Eghbali-Fatourechi E., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early post-menopausal women. J Clin Invest 2003, 111:1221-1230.
90. Gospodarowicz D. Fibroblast growth factor. Clin Orthop Relat Res 1990, 257:231-248.
91. Jee W.S.S., Ke H.Z., Li X.J. Long-term anabolic effects of prostaglandin-E2 on tibial diaphyseal bone in male rats. Bone Miner 1991, 15:33-55.
92. Boyce B.F., Aufdemorte T.B., Garrett I.R., Yates A.J.P., Mundy G.R. Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 1989, 125:1142-1150.
93. Noda M., Camilliere J.J. In vivo stimulation of bone formation by transforming growth factor. Endocrinology 1989, 124:2991-2994.
94. Nakamura T., Hanada K., Tamura M., Shibanushi T., Nigi H., Tagawa M., Fukumoto S., Matsumoto T. Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats. Endocrinology 1995, 136:1276-1284.
95. Folkman J. Angiogenesis in cancer, vascular rheumatoid and other disease. Nature Med 1995, 1:27-31.
96. Harada S., Nagy J.A., Sullivan K.A., Thomas K.A., Endo N., Rodan G.A., Rodan S.B. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J Clin Invest 1994, 93:2490-2496.
97. Niida S., Kaku M., Amano H., Yoshida H., Kataoka H., Nishikawa S., Tanne K., Maeda N., Nishikawa S., Kodama H. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 1999, 190:293-298.
98. Horwood N.J., Kartsogiannis V., Quinn J.M.W., Romas E., Martin T.J., Gillespie M.T. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999, 265:144-150.
99. Kong Y.Y., Feige U., Sarosil U., Bolon B., Tafuri A., Morony S., Capparelli C., Li J., Elliott R., McCabe S., Wong T., Campagnuolo G., Moran E., Bogoch E.R., Van G., Nguyen L.T., Ohashi P.S., Lacey D.L., Fish E., Boyle W.J., Penninger J.M. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
100. Giachelli C.M., Bae N., Almeida M., Denhardt D.T., Alpers C.E., Schawrtz S.M. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993, 92:1686-1696.
101. O'Brien E.R., Garvin M.R., Stewart D.K., Hinohara T., Simpson J.B., Schwatz S.M., Giachelli C.M. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 1994, 14:1648-1656.
102. Christian J.C., Slemenda C., Johnston C.C. Heritability of bone mass: A longitudinal study in aging male twins. Am J Hum Genet 1989, 44:429-433.
103. Morrison N.A., Cheng Qi J., Tokita A., Kelly P.J.H., Crofts L., Nguyen T.V., Sambrook P.N., Eisman J.A. Prediction of bone density from vitamin D receptor alleles. Nature 1994, 367:284-287.
104. Spotila L.D., Constantinou C.D., Sereda L., Ganguly A., Riggs B.L., Prockop D.J. Mutation in a gene for type 1 procollagen (COL1A2) in a woman with post-menopausal osteoporosis: Evidence for phenotypic and genotypic overlap with mild osteogenesis imperfecta. Proc Natl Acad Sci USA 1991, 88:5423-5427.
105. Smith E.P., Boyd J., Frank G.R., Takahashi H., Cohen R.M., Specker B., Williams T.C., Lubahn D.L.B., Korach K.S. Estrogen resistance caused by mutation in the estrogen-receptor gene in a man. N Engl J Med 1994, 331:1056-1061.
106. Lubahn D.B., Moyer J.S., Golding T.S., Couse J.F., Korach K.S., Smithies O. Alteration of reproductive function but not prenatal sequal development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 1993, 90:11162-11166.
107. Korach K.S. Insights from the study of animals lacking functional estrogen receptor. Science 1994, 266:1524-1527.
108. Oursler M.J., Pederson L., Fitzpatrick L., Riggs B.L., Spelsberg T. Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc Natl Acad Sci USA 1994, 91:5227-5231.
109. Frost H.M. The mechanosts: A proposed pathogenic mechanism of osteoporosis and the bone mass effects of mechanical and nonmechanical agents. Bone 1987, 2:783-785.
110. Thompson D.T., Rodan G.A. Indomethacin inhibition of tenotomy-induced bone resorption in rats. J Bone Miner Res 1988, 3:409-414.
111. Mosekilde L. Consequences of the remodeling process for vertebral trabecular bone structure: A scanning electron microscopy study (uncoupling of loaded structures). Bone Mineral 1990, 10:13-35.
112. Bonadio J., Jepsen K.J., Mansoura M.K., Jaenisch R., Huhn J.L., Goldstein S.A. A murine skeletal adaptation that significantly increases cortical bone mechanical properties. J Clin Invest 1993, 92:1697-1705.
113. Lafage M.H., Balena R., Battle M.A., Shea M., Seedor J.G., Klein H., Hayes W.C., Rodan G.A. Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. J Clin Invest 1995, 95:2127-2133.
114. Rubin C.T., Lanyon L.E. Regulation of bone mass by mechanical strain magnitude. Calcif Tissue Int 1985, 37:411-417.
115. Schneider V., Ogancy V., LeBlanc A., Rakhmanov A., Bakulin A., Grigoriev A., VarRonin L. Spaceflight bone loss and changes in fat and lean body mass. J Bone Miner Res 1992, 7:S122.
116. Huddleston A.L., Rockwell D., Kulund D.N., Harrison R.B. Bone mass in lifetime tennis athletes. JAMA 1980, 244:1107-1109.
117. Morii S., Burr D.B. Increased intracortical remodeling following fatigue damage. Bone 1993, 14:103-109.
118. Kornberg L.J., Earp S.H., Turner C.E., Prockop C., Juliano R.L. Signal transduction by integrins: Increased protein tyrosine phosphorylation caused by clustering beta-l integrins. Proc Natl Acad Sci USA 1991, 88:8392-8396.
119. Silverberg S.J., Gartenberg F., McMahon D., Bilezikian J.P. Parathyroidectomy improves bone density at cancellous sites in asymptomatic primary hyperparathyroidism. J Bone Miner Res 1993, 8:S169.
120. Shinar D., Rodan G.A. Relationships and interactions between bone and bone marrow. The Hematopoietic Microenvironment: The Functional and Structural Basis of Blood Cell Development 1993, 79-109. Johns Hopkins University Press, Baltimore, MD. M.W. Long, M.S. Wicha (Eds.).
121. Ducy P., Amling M., Takeda S., Priemel M., Schilling A.F., Beil F.T., Shen J., Vinson C., Rueger J.M., Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 2000, 100:197-207.